Teva Pharm Stock Price, News & Analysis

Teva Pharmaceutical (NYSE: TEVA) has launched tender offers to purchase up to $2 billion worth of senior notes due between 2026-2031. The tender offers cover six series of notes issued by Teva's finance subsidiaries and guaranteed by Teva, including both USD and EUR denominated securities. The offers are structured in three pools with specific caps: Pool 1 ($1.55B max), Pool 2 ($250M equivalent max), and Pool 3 ($200M equivalent max). Holders tendering by June 2, 2025 (Early Tender Time) will receive the Total Consideration including a $50/€50 premium per $1,000/€1,000 principal amount. The offers expire on June 17, 2025. Teva plans to fund these purchases through a new debt offering and cash on hand, aiming to proactively manage its debt structure and extend its maturity profile.

Teva Pharmaceutical announced a $2 billion senior notes offering through its finance subsidiaries. The offering includes both EUR-denominated and USD-denominated notes. The company plans to use the proceeds, along with cash on hand, to fund tender offers for several existing senior notes due between 2026 and 2031, with a maximum combined purchase price of up to $2 billion. Any remaining proceeds will be used for repaying outstanding debt. The notes will be unsecured senior obligations of the issuers and will be unconditionally guaranteed by Teva. The offering will be made through Teva's automatic shelf registration statement on Form S-3, filed with the SEC on February 7, 2025.

Teva Pharmaceuticals (TEVA) has received a credit rating upgrade from Moody's Investor Services, raising the company's corporate credit rating to Ba1 with a stable outlook from Ba2 with a positive outlook. The upgrade reflects Teva's significant global presence, growth in branded franchises, stabilization of its generics business, and successful debt reduction efforts. According to CFO Eli Kalif, this upgrade validates the success of Teva's Pivot to Growth strategy and is expected to result in improved debt costs and broader access to investors.

Teva Pharmaceutical (NYSE: TEVA) published its 2024 Healthy Future Report, highlighting significant sustainability achievements. The company surpassed several key targets ahead of schedule, including a 29% reduction in greenhouse gas emissions (exceeding 25% target) and launching nine access to medicine programs (surpassing target of eight). Teva donated approximately 18 million doses of medicine worth $23 million and provided 2.2 million doses at low cost, reaching 187,000 patients. The company achieved strong compliance metrics with 99% of employees trained on ethics and 41% of significant suppliers evaluated for sustainability. Teva's generic medicines contributed to $39.7 billion in healthcare savings across 22 countries. The company received improved sustainability scores from rating organizations, including its highest score from EcoVadis, demonstrating progress in environmental, social, and governance initiatives.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its upcoming Innovation & Strategy Day, scheduled for Thursday, May 29, 2025, in New York City. The event will run from 8:30 AM to 12:30 PM Eastern Time. CEO Richard Francis and the executive management team will present updates on the company's strategy, focusing on the acceleration phase, growth initiatives, and innovation priorities.

Due to limited capacity, in-person attendance is invitation-only, with analysts and institutional investors requiring pre-registration. A live webcast will be available on Teva's Investor Relations website, with archived content accessible within 24 hours after the event.

Teva (TEVA) reported strong Q1 2025 results, marking its ninth consecutive quarter of revenue growth. The company achieved revenues of $3.9 billion, a 5% increase in local currency terms. Key innovative medicines showed remarkable growth: AUSTEDO revenues reached $411 million (+39%), AJOVY hit $139 million (+26%), and UZEDY generated $39 million. The generics business grew across all regions. Teva improved its 2025 outlook, projecting revenues of $16.8-17.2 billion and non-GAAP EPS of $2.45-2.65. The company announced targeted programs to deliver ~$700 million in net savings by 2027, aiming to achieve a 30% operating margin. Q1 2025 showed solid performance with GAAP EPS of $0.18 and non-GAAP EPS of $0.52, an 8% year-over-year increase.

The FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with Stelara® (ustekinumab) for Teva Pharmaceuticals (TEVA) and Alvotech (ALVO). The approval, effective April 30, 2025, covers all presentations matching the reference product. SELARSDI is indicated for treating moderate to severe plaque psoriasis, active psoriatic arthritis in patients 6+ years, and moderately to severely active Crohn's disease and ulcerative colitis in adults. The drug is available in multiple presentations: 45 mg/0.5 mL and 90 mg/mL prefilled syringes, 45 mg/0.5 mL single-dose vial, and 130 mg/26 mL IV infusion vial. This marks Teva's second FDA-approved interchangeable biosimilar following SIMLANDI®, with three additional biosimilar candidates under FDA review with BsUFA goal dates in Q4 2025.

Teva Pharmaceuticals and Samsung Bioepis have announced the U.S. availability of EPYSQLI® (eculizumab-aagh), a biosimilar to Soliris®. The treatment is now accessible for patients with rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG) in AchR antibody positive adults.

EPYSQLI will be offered at a 30% discount compared to Soliris's Wholesale Acquisition Cost, making it one of the most cost-effective biosimilars in the U.S. The FDA approved EPYSQLI in July 2024 for PNH and aHUS treatments, with gMG indication added in November 2024.

Under their January 2025 partnership, Samsung Bioepis manages development, manufacturing, and supply, while Teva handles U.S. commercialization. The FDA has provisionally determined EPYSQLI to be interchangeable with Soliris® after exclusivity expiration for the first interchangeable biosimilar.

Teva Pharmaceuticals (NYSE: TEVA) announced the FDA's acceptance of its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab) to expand its use to pediatric episodic migraine prevention in patients aged 6-17 years weighing 45kg or more.

The application is supported by positive Phase 3 SPACE trial results, which showed statistically significant improvements in reducing monthly migraine and headache days versus placebo. If approved, AJOVY would become the first calcitonin gene-related peptide (CGRP) antagonist for both adult migraine prevention and pediatric episodic migraine prevention.

AJOVY, initially approved in the U.S. in 2018 for adult migraine prevention, is currently the only anti-CGRP treatment available in both quarterly and monthly dosing options. The treatment is also approved in Europe, Canada, Australia, and Japan.